Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Oklo Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Oklo Inc trades at $34.7 (market cap $6.43B). The key difference: Iovance Biotherapeutics Inc. Common Stock and Oklo Inc are close in size by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Oklo Inc for 32 Days on average.
| IOVA | OKLO | |
|---|---|---|
Market Cap | $6.04B | $6.43B |
Volume | 14,805,993 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $14.82 | $174.14 |
52-Week Low | $1.81 | $34.57 |
Typical Hold Time | 0 Days | 32 Days |
Enterprise Value | $5.97B | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKLO trades at $34.57, down 6.11% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, though analyst consensus remains strong with 71% buy ratings and a $78.63 price target. Recent news highlights nuclear industry momentum but questions OKLO's commercialization timeline versus established peers.
Outlook hinges on project execution amid substantial cash burn. High institutional financing supports growth but dilution risks persist. The stock offers speculative upside if nuclear contracts materialize, but faces near-term execution and competitive challenges in the small modular reactor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
